Archives of gynecology and obstetrics · 2009
Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Burges Alexander, Brüning Ansgar, Dannenmann Christine, Blankenstein Thomas, Jeschke Udo, Shabani Naim, Friese Klaus, Mylonas Ioannis
Аннотация
BACKGROUND: Ovarian cancer is a gynecologic cancer with a high mortality rate. This shows the need of effective screening methods and reliable cancer markers for ovarian cancer staging and appropriate effective cancer treatment.
METHODS: Expression of estrogen receptor alpha and beta was studied by immunhistochemical analysis of 100 ovarian cancer tissue samples.
RESULTS: In this study on 100 serous ovarian cancer tissue samples from patients with defined clinicopathologic features, a significant association of ER-alpha expression with ovarian cancer grading (p = 0.004), progression-free survival (p = 0.007), and cause-specific survival (p = 0.001) was demonstrated. Expression of ER-beta was found to be associated with the metastatic lymph node status (p = 0.006).
CONCLUSION: Immunohistochemical analysis of ER might be used as an easy, simple and highly efficient marker to identify high-risk patients and may aid in the selection of patients for a more aggressive adjuvant therapy. Furthermore, patients that show a positive ER-alpha immunostaining can be selected for a specific anti-hormonal therapy, as already performed for breast cancer patients.
METHODS: Expression of estrogen receptor alpha and beta was studied by immunhistochemical analysis of 100 ovarian cancer tissue samples.
RESULTS: In this study on 100 serous ovarian cancer tissue samples from patients with defined clinicopathologic features, a significant association of ER-alpha expression with ovarian cancer grading (p = 0.004), progression-free survival (p = 0.007), and cause-specific survival (p = 0.001) was demonstrated. Expression of ER-beta was found to be associated with the metastatic lymph node status (p = 0.006).
CONCLUSION: Immunohistochemical analysis of ER might be used as an easy, simple and highly efficient marker to identify high-risk patients and may aid in the selection of patients for a more aggressive adjuvant therapy. Furthermore, patients that show a positive ER-alpha immunostaining can be selected for a specific anti-hormonal therapy, as already performed for breast cancer patients.